Uniqure NV Company Profile (NASDAQ:QURE)

About Uniqure NV (NASDAQ:QURE)

Uniqure NV logouniQure N.V. (uniQure) is a gene therapy company. The Company is engaged in developing single treatments with curative results for patients suffering from genetic and other severe diseases. The Company is advancing a focused pipeline of gene therapies that have been developed both internally and through partnerships. The Company's product candidates include AMT-060 for Hemophilia B, AMT-130 for Huntington's disease, S100A1 for congestive heart failure and Glybera for lipoprotein lipase deficiency (LPLD). uniQure has established clinical proof-of-concept in its lead indication, hemophilia B and has achieved pre-clinical, proof-of-concept in Huntington's disease. The Company, through its collaboration with Bristol Myers-Squibb (BMS), is focused on building a portfolio of gene therapies led by the S100A1 program for congestive heart failure.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:QURE
  • CUSIP: N/A
  • Web: www.uniqure.com
Capitalization:
  • Market Cap: $142.78 million
  • Outstanding Shares: 25,227,000
Average Prices:
  • 50 Day Moving Avg: $5.33
  • 200 Day Moving Avg: $5.94
  • 52 Week Range: $4.72 - $14.59
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.33
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $25.1 million
  • Price / Sales: 5.69
  • Book Value: $2.52 per share
  • Price / Book: 2.25
Profitability:
  • EBIDTA: ($65,940,000.00)
  • Net Margins: -370.57%
  • Return on Equity: -70.75%
  • Return on Assets: -30.99%
Debt:
  • Debt-to-Equity Ratio: 0.25%
  • Current Ratio: 7.34%
  • Quick Ratio: 7.33%
Misc:
  • Average Volume: 111,719 shs.
  • Beta: 0.15
  • Short Ratio: 6.14
 

Frequently Asked Questions for Uniqure NV (NASDAQ:QURE)

What is Uniqure NV's stock symbol?

Uniqure NV trades on the NASDAQ under the ticker symbol "QURE."

How were Uniqure NV's earnings last quarter?

Uniqure NV (NASDAQ:QURE) issued its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.64) by $0.16. The business had revenue of $3.32 million for the quarter, compared to the consensus estimate of $4.20 million. Uniqure NV had a negative return on equity of 70.75% and a negative net margin of 370.57%. View Uniqure NV's Earnings History.

When will Uniqure NV make its next earnings announcement?

Uniqure NV is scheduled to release their next quarterly earnings announcement on Monday, May, 29th 2017. View Earnings Estimates for Uniqure NV.

Where is Uniqure NV's stock going? Where will Uniqure NV's stock price be in 2017?

8 brokerages have issued 12-month price targets for Uniqure NV's shares. Their forecasts range from $8.00 to $27.00. On average, they expect Uniqure NV's share price to reach $16.57 in the next year. View Analyst Ratings for Uniqure NV.

What are analysts saying about Uniqure NV stock?

Here are some recent quotes from research analysts about Uniqure NV stock:

  • 1. Cowen and Company analysts commented, "QURE reported 1Q17 financials and presented multiple updates at ASGCT recently." (5/24/2017)
  • 2. According to Zacks Investment Research, "UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands. " (5/17/2017)

Are investors shorting Uniqure NV?

Uniqure NV saw a drop in short interest in April. As of April 28th, there was short interest totalling 791,926 shares, a drop of 1.7% from the April 13th total of 805,786 shares. Based on an average trading volume of 103,086 shares, the short-interest ratio is currently 7.7 days.

Who are some of Uniqure NV's key competitors?

Who owns Uniqure NV stock?

Uniqure NV's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (5.94%), Perceptive Advisors LLC (5.02%), Morgan Stanley (2.24%), Renaissance Technologies LLC (1.48%), Spark Investment Management LLC (1.22%) and Boston Partners (1.07%). View Institutional Ownership Trends for Uniqure NV.

Who sold Uniqure NV stock? Who is selling Uniqure NV stock?

Uniqure NV's stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE and Spark Investment Management LLC. View Insider Buying and Selling for Uniqure NV.

Who bought Uniqure NV stock? Who is buying Uniqure NV stock?

Uniqure NV's stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, P.A.W. Capital Corp, Renaissance Technologies LLC, Paloma Partners Management Co, Morgan Stanley, Weiss Multi Strategy Advisers LLC, Oxford Asset Management and JPMorgan Chase & Co.. View Insider Buying and Selling for Uniqure NV.

How do I buy Uniqure NV stock?

Shares of Uniqure NV can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Uniqure NV stock cost?

One share of Uniqure NV stock can currently be purchased for approximately $5.66.

Analyst Ratings

Consensus Ratings for Uniqure NV (NASDAQ:QURE) (?)
Ratings Breakdown: 2 Hold Ratings, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $16.57 (192.78% upside)

Analysts' Ratings History for Uniqure NV (NASDAQ:QURE)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/24/2017Cowen and CompanyReiterated RatingBuyLowView Rating Details
5/16/2017Oppenheimer Holdings Inc.Set Price TargetBuy$17.00MediumView Rating Details
4/12/2017Jefferies Group LLCReiterated RatingHold$8.00LowView Rating Details
1/30/2017Chardan CapitalReiterated RatingPositive$12.00N/AView Rating Details
12/2/2016Leerink SwannReiterated RatingOutperformN/AView Rating Details
12/6/2016WallachBeth CapitalLower Price TargetBuy$27.00 -> $15.00N/AView Rating Details
11/15/2016Piper Jaffray CompaniesDowngradeOverweight -> NeutralN/AView Rating Details
8/4/2016HC WainwrightInitiated CoverageBuy$21.00N/AView Rating Details
1/8/2016Janney Montgomery ScottReiterated RatingBuyN/AView Rating Details
1/8/2016Roth CapitalReiterated RatingBuy$37.00N/AView Rating Details
(Data available from 5/25/2015 forward)

Earnings

Earnings History for Uniqure NV (NASDAQ:QURE)
Earnings by Quarter for Uniqure NV (NASDAQ:QURE)
Earnings History by Quarter for Uniqure NV (NASDAQ:QURE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/29/2017        
5/9/20173/31/2017($0.64)($0.80)$4.20 million$3.32 millionViewN/AView Earnings Details
5/31/2016Q1($0.82)($0.93)$2.94 million$4.30 millionViewN/AView Earnings Details
4/4/2016Q415($0.60)($0.58)$2.78 million$6.78 millionViewN/AView Earnings Details
11/30/2015Q315($0.64)($1.14)$7.76 million$3.50 millionViewListenView Earnings Details
8/27/2015Q215($0.56)($0.98)$31.18 million$1.79 millionViewN/AView Earnings Details
6/11/2015Q1($0.82)($0.69)$9.50 million$1.17 millionViewN/AView Earnings Details
4/6/2015($0.62)($0.77)$1.38 million$1.61 millionViewN/AView Earnings Details
12/1/2014($0.53)($0.61)$2.00 million$1.30 millionViewN/AView Earnings Details
9/2/2014Q214($0.55)($1.35)$1.40 million$1.37 millionViewN/AView Earnings Details
6/6/2014($0.45)($0.52)$0.84 million$1.59 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Uniqure NV (NASDAQ:QURE)
2017 EPS Consensus Estimate: ($2.73)
2018 EPS Consensus Estimate: ($2.44)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.71)($0.71)($0.71)
Q2 20172($0.81)($0.71)($0.76)
Q3 20171($0.77)($0.77)($0.77)
Q4 20171($0.49)($0.49)($0.49)
Q1 20181($0.73)($0.73)($0.73)
Q2 20181($0.67)($0.67)($0.67)
Q3 20181($0.69)($0.69)($0.69)
Q4 20181($0.35)($0.35)($0.35)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Uniqure NV (NASDAQ:QURE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Uniqure NV (NASDAQ:QURE)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Uniqure NV (NASDAQ:QURE)
Latest Headlines for Uniqure NV (NASDAQ:QURE)
Source:
DateHeadline
americanbankingnews.com logoCowen and Company Reaffirms "Buy" Rating for Uniqure NV (QURE)
www.americanbankingnews.com - May 24 at 4:32 PM
americanbankingnews.com logoShort Interest in Uniqure NV (QURE) Drops By 1.7%
www.americanbankingnews.com - May 22 at 9:16 PM
americanbankingnews.com logoFY2017 EPS Estimates for Uniqure NV (QURE) Decreased by Analyst
www.americanbankingnews.com - May 18 at 10:38 AM
americanbankingnews.com logoUniqure NV (QURE) PT Set at $17.00 by Oppenheimer Holdings Inc.
www.americanbankingnews.com - May 17 at 7:10 PM
americanbankingnews.com logoUniqure NV (QURE) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - May 17 at 7:48 AM
americanbankingnews.com logoUniqure NV (QURE) Forecasted to Earn Q2 2017 Earnings of ($0.81) Per Share
www.americanbankingnews.com - May 17 at 7:42 AM
globenewswire.com logouniQure Presents New Data Demonstrating Successful and Effective Transduction of AAV5 Vector in the Presence of ... - GlobeNewswire (press release)
globenewswire.com - May 12 at 8:04 AM
streetinsider.com logouniQure (QURE) Presents Data on Successful Readministration of Gene Therapy in Non-Human Primates - StreetInsider.com
www.streetinsider.com - May 12 at 8:04 AM
finance.yahoo.com logouniQure Announces Successful Readministration of Gene Therapy in Non-Human Primates
finance.yahoo.com - May 11 at 8:22 AM
americanbankingnews.com logoUniqure NV (QURE) Posts Earnings Results, Misses Expectations By $0.16 EPS
www.americanbankingnews.com - May 10 at 4:56 PM
streetinsider.com logoForm 8-K uniQure NV For: May 09 - StreetInsider.com
www.streetinsider.com - May 10 at 11:20 AM
reuters.com logoBRIEF-Uniqure NV Q1 loss per share $0.80 - Reuters
www.reuters.com - May 10 at 11:20 AM
finance.yahoo.com logouniQure Presents New Data Demonstrating Successful and Effective Transduction of AAV5 Vector in the Presence of Pre-Existing Neutralizing Antibodies in Non-Human Primates
finance.yahoo.com - May 10 at 11:20 AM
cnbc.com logoUniQure reports 1Q loss
www.cnbc.com - May 9 at 10:53 AM
reuters.com logoBRIEF-Uniqure NV Q1 loss per share $0.80
www.reuters.com - May 9 at 10:53 AM
finance.yahoo.com logouniQure Announces First Quarter 2017 Financial Results and Highlights Recent Company Progress
finance.yahoo.com - May 9 at 10:53 AM
americanbankingnews.com logoUniqure NV (QURE) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 9 at 8:46 AM
americanbankingnews.com logoUniqure NV (QURE) Receiving Somewhat Positive News Coverage, Study Finds
www.americanbankingnews.com - May 3 at 1:09 AM
globenewswire.com logouniQure Announces Company Presentations at Upcoming May Conferences - GlobeNewswire (press release)
globenewswire.com - May 2 at 9:52 AM
americanbankingnews.com logo-$0.69 EPS Expected for Uniqure NV (QURE) This Quarter
www.americanbankingnews.com - May 1 at 7:44 PM
finance.yahoo.com logouniQure Announces Company Presentations at Upcoming May Conferences - Yahoo Finance
finance.yahoo.com - May 1 at 10:39 AM
finance.yahoo.com logouniQure Announces Company Presentations at Upcoming May Conferences
finance.yahoo.com - May 1 at 10:39 AM
americanbankingnews.com logoUniqure NV (QURE) Earns Media Impact Rating of 0.44
www.americanbankingnews.com - April 28 at 12:14 PM
streetinsider.com logouniQure (QURE) Presents New Preclinical Data on AMT-130 in HD - StreetInsider.com
www.streetinsider.com - April 27 at 10:48 AM
finance.yahoo.com logouniQure Presents New Preclinical Data on AMT-130 in Huntington’s Disease at CHDI’s 12th Annual Huntington’s Disease Therapeutics Conference
finance.yahoo.com - April 26 at 5:50 PM
finance.yahoo.com logouniQure Announces Presentations at the Upcoming Annual Meeting of The American Society of Gene and Cell ... - Yahoo Finance
finance.yahoo.com - April 25 at 10:17 AM
globenewswire.com logouniQure Receives European Medicines Agency Priority Medicines (PRIME) Designation for AMT-060 in Hemophilia B - GlobeNewswire (press release)
globenewswire.com - April 25 at 10:17 AM
finance.yahoo.com logouniQure Receives European Medicines Agency Priority Medicines (PRIME) Designation for AMT-060 in Hemophilia B
finance.yahoo.com - April 25 at 10:17 AM
americanbankingnews.com logoUniqure NV (QURE) Given Media Sentiment Rating of 0.22
www.americanbankingnews.com - April 24 at 7:48 PM
finance.yahoo.com logouniQure Announces Presentations at the Upcoming Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)
finance.yahoo.com - April 24 at 5:55 PM
News IconBRIEF-uniQure to not seek Glybera marketing authorization renewal in Europe
www.businessinsider.com - April 21 at 7:15 PM
streetinsider.com logoForm 8-K uniQure NV For: Apr 19 - StreetInsider.com
www.streetinsider.com - April 21 at 8:41 AM
finance.yahoo.com logoBiotech firm pulls pioneering gene therapy due to no demand
finance.yahoo.com - April 20 at 7:33 PM
globenewswire.com logouniQure Announces It Will Not Seek Marketing Authorization Renewal for Glybera in Europe - GlobeNewswire (press release)
globenewswire.com - April 20 at 8:38 AM
finance.yahoo.com logouniQure Announces It Will Not Seek Marketing Authorization Renewal for Glybera in Europe
finance.yahoo.com - April 20 at 8:38 AM
americanbankingnews.com logoUniqure NV (QURE) Earns "Hold" Rating from Jefferies Group LLC
www.americanbankingnews.com - April 18 at 8:59 AM
americanbankingnews.com logoUniqure NV (QURE) Receiving Somewhat Positive Press Coverage, Report Shows
www.americanbankingnews.com - April 17 at 4:22 PM
americanbankingnews.com logoUniqure NV (QURE) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 14 at 9:54 AM
americanbankingnews.com logoUniqure NV (QURE) Getting Somewhat Favorable Media Coverage, Study Finds
www.americanbankingnews.com - April 13 at 7:47 PM
americanbankingnews.com logoUniqure NV's (QURE) "Hold" Rating Reiterated at Jefferies Group LLC
www.americanbankingnews.com - April 12 at 3:53 PM
americanbankingnews.com logo$5.58 Million in Sales Expected for Uniqure NV (QURE) This Quarter
www.americanbankingnews.com - April 12 at 11:54 AM
finance.yahoo.com logouniQure Publishes Data Demonstrating Wide Distribution of AAV5 in the Central Nervous System
finance.yahoo.com - April 7 at 12:10 PM
globenewswire.com logouniQure Announces Presentations at Upcoming April Conferences - GlobeNewswire (press release)
globenewswire.com - April 3 at 11:57 PM
finance.yahoo.com logouniQure Announces Presentations at Upcoming April Conferences
finance.yahoo.com - April 3 at 9:01 AM
seekingalpha.com logoUniqure's Hemophilia B FIX Replacement Therapy Has Potential
seekingalpha.com - March 29 at 8:15 PM
americanbankingnews.com logoUniqure NV Forecasted to Earn Q1 2017 Earnings of ($0.71) Per Share (QURE)
www.americanbankingnews.com - March 27 at 7:44 AM
americanbankingnews.com logoUniqure NV's (QURE) "Buy" Rating Reaffirmed at Oppenheimer Holdings Inc.
www.americanbankingnews.com - March 24 at 10:25 PM
seekingalpha.com logoUniqure NV (QURE) Presents At Oppenheimer 27th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 22 at 7:23 PM
finance.yahoo.com logoUNIQURE N.V. Financials
finance.yahoo.com - March 21 at 7:12 PM
streetinsider.com logoForm 8-K uniQure N.V. For: Mar 15 - StreetInsider.com - StreetInsider.com
www.streetinsider.com - March 16 at 8:22 AM

Social

Chart

Uniqure NV (QURE) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by MarketBeat.com Staff